Armand Butera

Investigators propose oral treprostinil be considered when treating patients with pulmonary arterial hypertension.

Patients treated with the monoclonal antibody had increased incidences of conjunctivitis, though many of these incidences were considered mild and were resolved by the end of the study.

A higher proportion of newly diagnosed patients with PAH showed improved risk status after the initiation of the oral prostacyclin receptor agonist.

Investigators noted that the agonist was particularly effective in patients with severe PAH who were receiving spironolactone.

The approval was supported by promising phase 3 data of the VOLTAIRE-X clinical trial.

New data reveals that the pandemic led to significantly less medicines being taken by pediatric patients during the first lockdown in Finland.

Investigators call the combination of intralesional corticosteroid injections and narrow-band ultraviolet B light to be “effective, simple, and relatively safe”.

Investigators believe these data have the potential to be targeted in new drug therapies for the reduction of allergic rhinitis symptoms.

Data from the PAUSE clinical trial reveals that more participants experienced psoriasis relapse in the abatacept group than the ustekinumab group.

Investigators reported a 3% difference in clinically relevant bleeding in participants treated with rivaroxaban and aspirin.

Investigators collected data from several studies which tested the efficacy of the ointment on pediatric populations affected by atopic dermatitis and their families.

Investigators reported that machine learning was non-invasive and accessible to a large array of clinicians, and could help prevent infants from developing atopic dermatitis.

Investigators believe that pediatric patients can gain the most from a combination of interventions, though larger studies are needed to confirm the data.

Dr. Maguiness speaks of new forms of tinea capitis not traditionally seen in the United States, as well as common practices shared between parents and clinicians for the management of several hair and nail disorders.

Dr. Hawryluk noted that acne is estimated to affect 35%-95% of pediatric patients worldwide, though proper diagnosis and treatment of this dermatological condition is possible.

Dr. Owotomo and fellow investigators evaluated 1298 children from the Washington DC area and found that called for greater asthma care by pulmonologists and allergists alike.

Dr. Hawryluk speaks of improving upon tolerability of existing therapies for atopic disease as well as promising new therapies on the horizon.

Cohen believes the emergency injection is not only cost-effective but the ideal treatment method for protecting vulnerable pediatric groups with allergies.

Cohen details some of the diagnostic criteria for anaphylaxis in pediatric populations, differences in symptoms among children and adolescents, and the virtues of epinephrine.

Dr. De Keyser highlights the success of biologics such as omalizumab and dupilumab in the treatment of asthma and atopic dermatitis in pediatric populations.

Dr. Hernandez-Trujilo speaks of her personal history with food allergy, and what she recommends for families and expecting parents in the management of pediatric food allergy.

Prior to the investigation, peanut allergy was often linked to high rates of anaphylaxis, with its prevalence in children and adolescents surpassing that found in adult patients.

The long-term study from Denmark also found a strong association between gender and loss of asthma control, among other factors.

Investigators believe the reduction of DIF usage could result in cost reductions without compromising patient care.

Investigators from Egypt recorded a high prevalence of stress, anxiety, and depression in patients with vitiligo.

Investigators call for pollen monitoring that provides free, continuous, real‐time pollen data representative for any given region.

Delgocitinib is the first and only topical JAK/STAT pathway inhibitor in Japan, and recent data suggests it is effective in the management of atopic dermatitis.

Dr. Lawrence Eichenfield and Dr. David Rosmarin speak to the efficacy of topical ruxolitinib displayed in several trials involving patients with atopic dermatitis and vitiligo.

Investigators also found that patients with alopecia areata were also had significant inflammatory immune injury and vitamin D deficiency when compared to healthy subjects.

Dr. Paller speaks of the AD-GAP study, which shared insights on moderate to severe atopic dermatitis from patients, caregivers, and independent physicians.